Middle East & Africa As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover that the volatility of these geographies often meant that the expected returns did not materialise. However, especially post-COVID, emerging markets…
Hong Kong Since first allowing pre-revenue biotechs to list in 2018, the Hong Kong stock exchange has welcomed 59 such companies and is now a leading vehicle for allowing Chinese biopharma to access international capital. Christina Bao, HKEX’s co-head of sales and marketing, discusses listing momentum picking up again after a rocky…
UAE CSL Behring – which specalises in plasma-derived, and recombination therapeutic products – has undergone significant expansion in the Middle East and Africa (MEA) region in recent years under Hassan Herrou. He explains why building partnerships with the relevant authorities as well as patient associations is vital to fostering access in…
Hong Kong The Hong Kong Association of the Pharmaceutical Industry (HKAPI) represents the interests of the global R&D-based biopharmaceutical industry in Hong Kong and Macau. Senior Executive Director Sabrina Chan outlines the access to innovation scenario in the territory today, the niches in which Hong Kong stands out from the crowd as…
UAE NewBridge Pharmaceuticals’ Joe Henein describes how his MENA-focused specialty innovative biopharma distributor has developed over the last 13 years to become a market leader; looks at some of the key trends shaping the market in his region; and reinforces his commitment to bridging the gap and delivering therapies to patients…
Hong Kong AstraZeneca, the largest overseas pharmaceutical company in mainland China by sales, is also the market leader in Hong Kong and Macau, a territory overseen by General Manager Shan Wu. She outlines the fundamentals behind the company’s success in Greater China, how AstraZeneca is working to bolster Hong Kong’s innovation and…
China A roundup of some of the latest healthcare and pharma news from China including a crackdown on healthcare corruption; AstraZeneca’s cardiovascular mortality drug approval and mRNA manufacturing deal with CanSino; Tigermed’s new Hong Kong HQ; GenScript Biotech/T-Maximum Biotech CAR-T agreement, and the Chinese cabinet’s renewed efforts to encourage foreign biotech…
China First set up in 2014, the Guangdong Medical Valley is an investment incubation platform in southern China focusing on the biomedical and medical device industries. CEO Xia Jiasheng explains how the decision to set up the cluster came about, how it differs from the wealth of other science parks in…
Hong Kong Fresh from the news that one of its AI-designed and discovered drug candidates has entered Phase II human clinical trials – the first time that such a project has made it to that development stage – Insilico Medicine’s Alex Zhavoronkov sat down with PharmaBoardroom to discuss a range of topics.…
UAE Less than two years into position as CEO of MENA-wide pharma and consumer health player Dar Al Dawa, Khaled Harb looks back on what has already been achieved and the ambitious strategy he has put in place for the short-, medium-, and long-term. Harb also outlines some of the key…
UAE Mohamed Abu Shawish discusses some of the core challenges facing rare disease patients in the GCC region and how Kyowa Kirin is engaging in multi-stakeholder partnerships across the healthcare sector to help solve them. It is important that if a patient is diagnosed, the treatment is always readily available,…
Hong Kong The Guangzhou production site of HKEX-listed RNA therapeutics biotech Sirnaomics is overseen by pharma industry veteran Edward Wang. Here, Wang explains his contribution to the development of good manufacturing practices (GMP) in China and why southern China makes sense as a manufacturing location for a local biotech with global ambitions.…
See our Cookie Privacy Policy Here
